236 related articles for article (PubMed ID: 35332389)
21. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
Williams DS; Mouradov D; Browne C; Palmieri M; Elliott MJ; Nightingale R; Fang CG; Li R; Mariadason JM; Faragher I; Jones IT; Churilov L; Tebbutt NC; Gibbs P; Sieber OM
Mod Pathol; 2020 Mar; 33(3):483-495. PubMed ID: 31471586
[TBL] [Abstract][Full Text] [Related]
22. Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
Kenseth A; Kantorova D; Seo MK; Aas E; Cairns J; Kerr D; Askautrud H; Jacobsen JE
Pharmacoeconomics; 2024 Jun; 42(6):679-691. PubMed ID: 38584239
[TBL] [Abstract][Full Text] [Related]
23. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
24. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
25. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
27. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
Boye K; Jacob H; Frikstad KA; Nesland JM; Maelandsmo GM; Dahl O; Nesbakken A; Flatmark K
Cancer Med; 2016 Aug; 5(8):1840-9. PubMed ID: 27273130
[TBL] [Abstract][Full Text] [Related]
29. MiR-320e is a novel prognostic biomarker in colorectal cancer.
Perez-Carbonell L; Sinicrope FA; Alberts SR; Oberg AL; Balaguer F; Castells A; Boland CR; Goel A
Br J Cancer; 2015 Jun; 113(1):83-90. PubMed ID: 26035698
[TBL] [Abstract][Full Text] [Related]
30. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
Skrede OJ; De Raedt S; Kleppe A; Hveem TS; Liestøl K; Maddison J; Askautrud HA; Pradhan M; Nesheim JA; Albregtsen F; Farstad IN; Domingo E; Church DN; Nesbakken A; Shepherd NA; Tomlinson I; Kerr R; Novelli M; Kerr DJ; Danielsen HE
Lancet; 2020 Feb; 395(10221):350-360. PubMed ID: 32007170
[TBL] [Abstract][Full Text] [Related]
31. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
32.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
33. HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer.
Feng Y; Li Y; Huang D; Cai S; Peng J
Eur J Surg Oncol; 2019 Feb; 45(2):167-173. PubMed ID: 30420187
[TBL] [Abstract][Full Text] [Related]
34. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
[TBL] [Abstract][Full Text] [Related]
35. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
36. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
[TBL] [Abstract][Full Text] [Related]
37. Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
Akabane S; Shimizu W; Takakura Y; Kochi M; Taguchi K; Nakashima I; Sato K; Hattori M; Egi H; Sentani K; Yasui W; Ohdan H
Int J Clin Oncol; 2021 Jul; 26(7):1285-1292. PubMed ID: 33881678
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
39. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
[TBL] [Abstract][Full Text] [Related]
40. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Cascinu S; Georgoulias V; Kerr D; Maughan T; Labianca R; Ychou M
Ann Oncol; 2003; 14 Suppl 2():ii25-9. PubMed ID: 12810454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
